FLT1 and melanoma: Consistently, in a murine syngeneic model of melanoma (B16F10 cells injected in B6D2F1 mice), VEGFR-1 targeting with the D16F7 mAb (six doses of 10 mg/kg administered on alternate days) inhibited melanoma growth and tumor infiltration by myeloid cells and, in particular, M2 macrophages, in vivo [120,122].